MSCI has announced a collaboration with Nasdaq-listed biopharmaceutical company Royalty Pharma to launch new indices that aim to capture themes that will disrupt the life sciences, biotechnology and pharmaceutical industry groups.

The initial indices will measure the performance of companies focused on delivering new and innovative therapeutic treatments related to virology and oncology.

MSCI will design a classification framework and index methodologies, with Royal Pharma to contribute industry and technical expertise. The indexes are planned to launch later this year. 


To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook